Marshwinds Advisory’s West Pharmaceutical WST Stock Holding History

Marshwinds Advisory’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-4,000	Closed	-$216K	–	139
2015 Q3	$216K	Hold	4,000	–	–	0.12%	129
2015 Q2	$232K	Hold	4,000	–	–	0.12%	129
2015 Q1	$241K	Hold	4,000	–	–	0.11%	133
2014 Q4	$213K	Buy	+4,000	New	+$200K	0.1%	136

Other funds holding WST

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Marshwinds Advisory's WST Position: Q4 2015 in Review

Marshwinds Advisory sold out of West Pharmaceutical (WST) in Q4 2015, closing a stake of 4,000 shares — an estimated $216K sold.

Marshwinds Advisory first reported a position in WST in Q4 2014 and held it in 4 quarters. The position peaked at $241K in Q1 2015. 249 funds tracked by Wall St. Rank hold WST as of Q4 2015.

Marshwinds Advisory reported no remaining West Pharmaceutical position as of Q4 2015 after selling out during the quarter.
Marshwinds Advisory sold 4,000 West Pharmaceutical shares in Q4 2015, an estimated $216K.
Marshwinds Advisory first reported a position in West Pharmaceutical in Q4 2014 and held it in 4 quarters.
Marshwinds Advisory's West Pharmaceutical position peaked at $241K in Q1 2015.
249 funds tracked by Wall St. Rank held West Pharmaceutical as of Q4 2015.

Based on Marshwinds Advisory's 13F filing for Q4 2015, filed 8 Jan 2016.